Genetically engineered anti-angiogenic anti-tumor cytotoxic lymphocytes: A novel immunotherapeutic strategy for malignant glioma

Principal Investigator: Richard C. Mulligan, PhD

Institute: Children’s Hospital

Initiative: Unrestricted Grant

Location: Boston, MA

Share